TITLE

Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain

AUTHOR(S)
Mercadante, Sebastiano; Vellucci, Renato; Cuomo, Arturo; Adile, Claudio; Cortegiani, Andrea; Valle, Alessandro; Villari, Patrizia; Casuccio, Alessandra
PUB. DATE
May 2015
SOURCE
Supportive Care in Cancer;May2015, Vol. 23 Issue 5, p1349
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: The aim of the present study was to assess the long-term tolerability and efficacy of intranasal fentanyl (INFS) in opioid-tolerant patients with breakthrough cancer pain (BTP). Patients and methods: A 6 months, observational, prospective, cohort study design was employed to follow advanced cancer patients with BTP receiving INFS under routine clinical practice. Eligible adult cancer patients suffering from BTP had been prescribed INFS at effective doses. Data were collected at T0 and at month intervals for six months. The principal outcomes were the evaluation of possible serious adverse effects with prolonged use of INFS, the efficacy of BTP treatment with INFS, the quality of sleep, the rate of INFS discontinuation, and reasons for that. Results: Seventy-five patients were surveyed. Thirty-four patients (45.3 %) had a follow-up at 3 months, and twelve patients (16 %) were followed up at 6 months. The mean opioid doses, expressed as oral morphine equivalents, ranged 111-180 mg/day, while the mean INFS doses were 87-119 μg. Adverse effects were reported in a minority of patients and were considered to be associated with opioid therapy used for background pain. The quality of sleep significantly improved during the first 3-4 months. Finally, efficacy based on a general impression regarding the efficacy of INFS was good-excellent in most patients and statistically improved in time up to the third month. Conclusion: The long-term use of INFS in advanced cancer patients is effective and safe. No serious adverse effects were found up to six months of assessment. The level of quality of sleep and patients' satisfaction was relatively good, considering the advanced stage of disease.
ACCESSION #
101793020

 

Related Articles

  • Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Davies, Andrew; Kleeberg, Ulrich; Jarosz, Jerzy; Mercadante, Sebastiano; Poulain, Philippe; O'Brien, Tony; Schneid, Hélène; Kress, Hans // Supportive Care in Cancer;Jul2015, Vol. 23 Issue 7, p2135 

    Purpose: This open-label study evaluated the effects of fentanyl buccal tablet (FBT) on functioning and mood in cancer patients with breakthrough cancer pain (BTcP). Methods: Opioid-tolerant patients in seven European countries with up to four BTcP episodes/day received FBT doses (100-800 μg)...

  • Fentanyl Nasal Spray.  // AHFS Consumer Medication Information;Sep2019, p1 

    Fentanyl nasal spray is used to treat breakthrough pain (sudden episodes of pain that occur despite round the clock treatment with pain medication) in cancer patients 18 years of age or older who are taking regularly scheduled doses of another narcotic (opiate) pain medication, and who are...

  • Fentanyl nasal spray manages cancer pain.  // Clinical Advisor;Dec2011, Vol. 14 Issue 12, p35 

    The article offers information on Fentanyl nasal spray, a drug used to manage cancer pain from Archimedes Pharma Ltd. It says that the drug can cure opiod-toletant patients experiencing pain, and acts on the mu-receptors in the central nervous system (CNS) to produce CNS depression and...

  • Intranasal Fentanyl for Breakthrough Pain Control. Clavijo, Claudia F.; Rzasa Lynn, Rachael; Christians, Uwe; Galinkin, Jeffrey L. // Clinical Medicine Insights: Therapeutics;2012, Issue 4, p241 

    Breakthrough pain (BTP) is experienced by approximately 65% of children and adults with chronic pain. Undiagnosed or untreated BTP produces negative emotional, physical, and economic consequences. BTP episodes have a rapid onset and short duration. Short acting oral opioids are the cornerstone...

  • Formulation Selection and Pharmacokinetic Comparison of Fentanyl Buccal Soluble Film with Oral Transmucosal Fentanyl Citrate. Vasisht, Niraj; Gever, Larry N.; Tagarro, Ignacio; Finn, Andrew L. // Clinical Drug Investigation;2009, Vol. 29 Issue 10, p647 

    Background and Objectives: BioErodible MucoAdhesive (BEMA®) is a new transmucosal drug delivery system designed to improve and ease the administration of drugs by this route. The first product that uses this novel delivery system contains fentanyl and is intended for the treatment of...

  • Fentanyl Pectin Nasal Spray: In Breakthrough Pain in Opioid-Tolerant Adults with Cancer. Lyseng-Williamson, Katherine A. // CNS Drugs;2011, Vol. 25 Issue 6, p511 

    Fentanyl pectin nasal spray (PecFent®) uses a novel pectin-based delivery system that turns from an aqueous solution into a gel when applied to mucosal surfaces. Fentanyl is absorbed in a controlled manner from the pectin gel formed in the nasal cavity, and has a rapid onset of pain relief...

  • EMERGENCY MEDICINE. Abbott, Leonie // Journal of Pharmacy Practice & Research;Mar2010, Vol. 40 Issue 1, p65 

    The article presents abstracts on drugs used in emergency medicine including the evidence-based use of bupivacaine for patients with hand injuries, the use of intranasal fentanyl for pediatric pain and the use of low-dose ketamine and morphine for people with bone fractures.

  • Recent innovations in breakthrough cancer pain management. Thai, Vincent // International Journal of Palliative Nursing;Feb2012 Supplement, p9 

    The article provides an overview of medications for breakthrough cancer pain (BtCP). The median duration of BtCP episodes is 45 to 60 minutes while the duration of effect of the standard rescue mediations is approximately 4 hours. Parenteral opioids can be regarded for BtCP treatment in certain...

  • Efficacy and Safety of Sublingual Fentanyl Tablets for the Management of Breakthrough Pain in Patients with Chronic Musculoskeletal Pain with Neuropathic Component: Multicenter Prospective Study. Cánovas-Martínez, Luz; Carceller-Ruiz, José; Díaz-Parada, Pilar; Illodo-Miramontes, Gustavo; Freire-Vila, Enrique; Iglesia-López, Aurora; Iglesias, Belén; López-Ulloa, Beatriz; Domínguez-Suárez, Enrique; Camba-Rodríguez, Alberto // Clinical Drug Investigation;Mar2015, Vol. 35 Issue 3, p169 

    Background and Objective: Despite its prevalence and impact, breakthrough pain (BTP) in chronic non-cancer pain with neuropathic component, has not been well studied and is sometimes unrecognized and often undertreated. We evaluated the efficacy of sublingual fentanyl tablet (SLF) for the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics